<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291499</url>
  </required_header>
  <id_info>
    <org_study_id>03CH/Ct06</org_study_id>
    <nct_id>NCT00291499</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand</brief_title>
  <official_title>Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg
      tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint
      osteoarthritis.

      Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's
      Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during
      the treatment with the tested product, Condrosulf®, versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg
      tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint
      osteoarthritis in 160 randomised patients.

      Primary endpoints:

      Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's
      Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during
      the treatment with the tested product, Condrosulf®, versus placebo.

      Secondary endpoints are:

      Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician
      (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of
      Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the
      treatment period; Other parameters:Treatment compliance; Biological markers of arthritis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of global spontaneous pain for both hands is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm and the score of Dreiser's algo-functional index (FIHOA).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global impression of efficacy.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength measured manometrically.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning stiffness duration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consupmtion of paracetamol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of arthritis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Chondroitin 4&amp;6 sulfate (Condrosulf)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin 4&amp;6 sulfate (Condrosulf)</intervention_name>
    <description>800 mg/day for 6 months</description>
    <arm_group_label>Chondroitin 4&amp;6 sulfate (Condrosulf)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>800 mg placebo/day for 6 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex

          -  Aged 40 and over

          -  Outpatients

          -  Patients fulfilling the ACR criteria for the reporting of hand OA

          -  Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP
             and 1 TMC) of the dominant hand on standard plain radiographs (&lt; 6 month).

          -  Suffering from regular spontaneous pain on the dominant hand (VAS &gt; or = 40 mm at
             inclusion time).

          -  Showing a FIHOA score &gt; or = 6.

          -  Having had at least two painful flares in a finger joint during the previous 12 month.

          -  Patients who have signed the written informed consent for their participation in the
             study

          -  Patients able to understand and follow the protocol.

          -  Patients with a satisfying health and nutritional status.

          -  Female subjects of childbearing potential using, within three months prior to the
             inclusion in the study, a reliable form of contraception during the course of the
             study (oral contraceptive pill, intrauterine device or condoms) or female of non
             childbearing potential (hysterectomy, bilateral ovariectomy or tubal
             section/ligation).

          -  Female subjects of childbearing potential with a negative urinary pregnancy test
             before the inclusion in the study.

        Exclusion Criteria:

          -  Inflammatory joint disease of other origin

          -  Septic arthritis

          -  Chronic inflammatory joint disease

          -  Previous articular fracture of the concerned articulations

          -  Use of analgesic therapy for other indications

          -  Receiving oral corticosteroids

          -  Mono-articular posttraumatic OA of the finger

          -  Planning surgery of the hands in the following 6 months

          -  Patients suffering or having suffered from secondary osteoarthritis after one of the
             following diseases:

               -  Infectious arthritis - Acromegaly

               -  Ochronosis - Hemachromatosis

               -  Gout - Wilson's disease

               -  Chondrocalcinosis - Paget's disease

               -  Osteochondrosis - Mutation of collagen

               -  Genetic problems (for ex. hypermobility) - Previous joint fracture

               -  Arthropathies of different aetiologies - Algodystrophy (M. Sudeck)

          -  Congenital abnormalities

          -  Recurrent pseudogout

          -  Major displasias

          -  Intra-articular injection in a hand joint from less than 3 months

          -  Basic treatment of arthritis with symptom-modifying agents (chondroitin sulfate,
             glucosamine sulfate, diacerrhein, hyaluronic acid) in the last 3 months

          -  Articular lavage in the last 3 months

          -  Treatment with corticoids, by any administration route during the last month

          -  Patient suffering from frequent asthma crises

          -  Physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture) on the
             hands foreseeable in the next year

          -  Serious organic diseases: heart failure, renal or hepatic insufficiency, blood
             dyscrasia, serious infection

          -  Participation in other clinical trials in the two months preceding the study

          -  Known or ascertained hypersensitivity to the active ingredient of the tested drug.

          -  Patients refusing to sign the written informed consent form

          -  Patients who do not co-operate, not respecting the protocol requirements

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cem Gabay, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUG Hôpitaux Universitaires de Genève</affiliation>
  </overall_official>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <reference>
    <citation>Lequesne M. [Symptomatic slow-action anti-arthritic agents: a new therapeutic concept?]. Rev Rhum Ed Fr. 1994 Feb;61(2):75-9. French.</citation>
    <PMID>7920505</PMID>
  </reference>
  <reference>
    <citation>Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86.</citation>
    <PMID>15751094</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004 Apr;12(4):269-76. Erratum in: Osteoarthritis Cartilage. 2007 Aug;15(8):979. DeVathaire, Florent [corrected to de Vathaire, Florent].</citation>
    <PMID>15023378</PMID>
  </reference>
  <reference>
    <citation>Cicuttini FM, Spector TD. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs Aging. 1995 May;6(5):409-20. Review.</citation>
    <PMID>7647428</PMID>
  </reference>
  <reference>
    <citation>Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am. 1993 Aug;19(3):713-24. Review.</citation>
    <PMID>8210583</PMID>
  </reference>
  <reference>
    <citation>Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 Oct;10(10):768-77.</citation>
    <PMID>12359162</PMID>
  </reference>
  <reference>
    <citation>Conte A, de Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung. 1991 Jul;41(7):768-72.</citation>
    <PMID>1772467</PMID>
  </reference>
  <reference>
    <citation>Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996 Aug;23(8):1385-91.</citation>
    <PMID>8856618</PMID>
  </reference>
  <reference>
    <citation>Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21.</citation>
    <PMID>9743814</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998 May;6 Suppl A:6-13.</citation>
    <PMID>9743813</PMID>
  </reference>
  <reference>
    <citation>Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30.</citation>
    <PMID>9743816</PMID>
  </reference>
  <reference>
    <citation>Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J, Masounabe-Puyanne A. [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72. French.</citation>
    <PMID>1485136</PMID>
  </reference>
  <reference>
    <citation>Bucsi L, Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998 May;6 Suppl A:31-6.</citation>
    <PMID>9743817</PMID>
  </reference>
  <reference>
    <citation>Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998 May;6 Suppl A:39-46.</citation>
    <PMID>9743819</PMID>
  </reference>
  <reference>
    <citation>Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998 May;6 Suppl A:37-8.</citation>
    <PMID>9743818</PMID>
  </reference>
  <reference>
    <citation>Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002 Jun;21(3):231-43.</citation>
    <PMID>12111630</PMID>
  </reference>
  <reference>
    <citation>Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum Engl Ed. 1995 Jun;62(6 Suppl 1):43S-53S.</citation>
    <PMID>7583182</PMID>
  </reference>
  <reference>
    <citation>Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990 Nov;33(11):1601-10.</citation>
    <PMID>2242058</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>symptomatic OA of the hand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

